This post was just published on ZYX Buy Change Alert. FOLD plans to submit a new drug application to FDA for the oral precision medicine migalastat for Fabry disease. The stock is jumping on the news. We are not recommending buying FOLD here but it can be part of a basket on
This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide intelligence
This post was just published on ZYX Buy Change Alert. For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens. Our rigorous criteria has led to enviable performance over a long period of time. We periodically provide
We have profits on both our long and short cancer trades. Our analysis indicates that it is time to either take profits and exit the positions or make stops extremely tight so that profits are locked in www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED
www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized
Per our earlier post, we are short on OSIP from $32.2, SNTA from $3.50and EXEL from $5.35.We are long on PARD from $4.45 www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed
Our review of the data presented at 2009 Annual Meeting of the American Society of Clinical Oncology held in Orlando shows that the following stocks may move in response to the data:SNTA,ZIOP,CLDX,EXEL,BVTI,ABII,OGXI,INFI,OSIP AND PARD. If the opening prices are not too far from the close, consider scaling in the premarket